Previous close | 436.00 |
Open | 430.00 |
Bid | 438.00 x 0 |
Ask | 440.00 x 0 |
Day's range | 430.00 - 430.00 |
52-week range | 406.00 - 549.10 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 18 Jul 2023 - 24 Jul 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), TotalEnergies SE (TTE) and Intuitive Surgical, Inc. (ISRG).
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Improving top line, investments in high-growth businesses, membership hikes and significant new contracts in its government business poise Elevance Health (ELV) well for growth.
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
INDIANAPOLIS, May 18, 2023--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the Bernstein 39th Annual Strategic Decisions Conference in New York City on June 1, at 8:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. You may also access the webcast by clicking on the following link https://kvgo.com/bernstein-2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Higher interest rates and plunging growth forecasts have been the economic fallout from inflation that has been elevated throughout some of 2021, all of 2022, and all this year so far. Given the essential nature of the goods and services provided by the healthcare sector, it is arguably one of the more durable economic sectors. Pfizer (NYSE: PFE) is probably best known today for its COVID-19 vaccine, Comirnaty, which it co-owns with BioNTech, and the COVID-19 antiviral treatment Paxlovid.
INDIANAPOLIS, May 05, 2023--Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at the 2023 RBC Capital Markets Global Healthcare Conference in New York City on May 17, at 8:00 a.m. Eastern Standard Time (EST). All interested parties are invited to listen to a webcast of the presentation by visiting www.elevancehealth.com and selecting the "Investors" link. Following the presentation, a webcast replay will be available for 90 days.
Cigna's (CI) first-quarter 2023 results indicate a strong contribution to revenues from Evernorth Health Services and Cigna Healthcare businesses. Management currently expects adjusted EPS to be a minimum of $24.70 in 2023.
Acadia Healthcare's (ACHC) Q1 results reflect higher revenue per patient day, partly offset by an elevated cost level. Management reaffirms its 2023 business guidance.
Teladoc Health's (TDOC) Q1 results reflect solid chronic care product revenues and improving access fees and other revenues.
ELV vs. AMEH: Which Stock Is the Better Value Option?
AMN Healthcare's (AMN) first-quarter results are likely to reflect soft demand across its segments.
Universal Health's (UHS) Q1 results reflect strong performance in acute care and behavioral health segments. Meanwhile, the elevated expense level partially offsets the positives.
Humana (HUM) expects adjusted EPS to be at least $28.25 in 2023, up from the previous guidance of $28 per share.
Centene's (CNC) first-quarter 2023 results grapple with higher operating expenses, partly offset by an expanding customer base. Management presently expects adjusted EPS to be at least $6.40 in 2023.
While the stock market tends to appropriately value stocks over the long run, this is far from always the case in the short term. The element of human emotion can often send stocks soaring or plunging beyond anything that their fundamentals would justify.
Elevance Health (ELV) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HCA Healthcare's (HCA) first-quarter results gain from increased patient admissions. Management expects EPS within the $17.25-$18.55 band this year, higher than the previous view of $16.40-$17.60.
Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.
The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Elevance Health (ELV) delivered earnings and revenue surprises of 2.16% and 2.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
INDIANAPOLIS, April 19, 2023--Elevance Health, Inc. (NYSE: ELV) reported first quarter 2023 results reflecting strong financial performance, including double-digit growth in revenue, operating earnings, and adjusted earnings per share.
ELV vs. DOCS: Which Stock Is the Better Value Option?
Elevance Health's (ELV) first-quarter results are likely to reflect higher premiums, commercial and government sales figures and total expenses.